A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade

Immune checkpoint inhibitors demonstrate clinical activity in many tumor types, however, only a fraction of patients benefit. Combining CD137 agonists with these inhibitors increases anti-tumor activity preclinically, but attempts to translate these observations to the clinic have been hampered by s...

Descripción completa

Detalles Bibliográficos
Autores principales: Geuijen, Cecile, Tacken, Paul, Wang, Liang-Chuan, Klooster, Rinse, van Loo, Pieter Fokko, Zhou, Jing, Mondal, Arpita, Liu, Yao-bin, Kramer, Arjen, Condamine, Thomas, Volgina, Alla, Hendriks, Linda J. A., van der Maaden, Hans, Rovers, Eric, Engels, Steef, Fransen, Floris, den Blanken-Smit, Renate, Zondag-van der Zande, Vanessa, Basmeleh, Abdul, Bartelink, Willem, Kulkarni, Ashwini, Marissen, Wilfred, Huang, Cheng-Yen, Hall, Leslie, Harvey, Shane, Kim, Soyeon, Martinez, Marina, O’Brien, Shaun, Moon, Edmund, Albelda, Steven, Kanellopoulou, Chrysi, Stewart, Shaun, Nastri, Horacio, Bakker, Alexander B. H., Scherle, Peggy, Logtenberg, Ton, Hollis, Gregory, de Kruif, John, Huber, Reid, Mayes, Patrick A., Throsby, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295259/
https://www.ncbi.nlm.nih.gov/pubmed/34290245
http://dx.doi.org/10.1038/s41467-021-24767-5

Ejemplares similares

Ejemplares similares